Biocardia

    [td_text_with_title custom_title=”Company description”]We are a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. BioCardia is developing proprietary comprehensive  biotherapeutic solutions for cardiovascular disease in its CardiAMP™ and CardiALLO™ therapies. Clinical results supporting both therapeutic programs are compelling and build upon the most rigorous data in the field to date with intramyocardial delivery of marrow-derived cells.

    These programs are enabled by the Company’s Helix transendocardial delivery systems and Morph® vascular access products, which are partnered to enable other promising biotherapeutic programs.

    BioCardia’s manufacturing facility is an FDA registered facility with California Devices Manufacturing License #63126, and has achieving certification to the ISO 13485:2003 Standard under the scope of design, development, manufacture and distribution of catheters for use in delivery of therapeutic agents directly to the heart, and of guiding catheters for use in peripheral and coronary vasculature and chambers of the heart.[/td_text_with_title]

    [td_text_with_title custom_title=”Latest post”]
    biocardia_ipo

    BioCardia files for a $58 million IPO

    SAN CARLOS, CA –BioCardia, Inc., a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs, announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to the proposed initial public offering (IPO) of shares of its common stock. […]

    0 comments
    [/td_text_with_title]